For instance, romidepsin, a select class I and II histone deacetylase (HDAC) inhibitor, extracted from Chromobacterium violaceum and was approved for treating cutaneous T-cell lymphoma (36). Here, HDAC9 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.